Powder: -20°C for 3 years | In solvent: -80°C for 1 year
XMD17-109 (ERK5-IN-1) 是一种特异性的ERK-5抑制剂,在 HEK293 细胞系中的EC50为 4.2 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 297 | 现货 | ||
2 mg | ¥ 457 | 现货 | ||
5 mg | ¥ 828 | 现货 | ||
10 mg | ¥ 1,490 | 现货 | ||
25 mg | ¥ 2,520 | 现货 | ||
50 mg | ¥ 3,760 | 现货 | ||
100 mg | ¥ 5,380 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,160 | 现货 |
产品描述 | XMD17-109 (ERK5-IN-1) is a new selective ERK-5 inhibitor (EC50: 4.2 uM, HEK293 cells). |
靶点活性 | ERK5:162 nM(EC50) |
体内活性 | 在细胞水平,ERK5-IN-1可抑制内皮生长因子诱导的ERK5自磷酸化(EC50:90 nM)。ERK5-IN-1对ERK5的生物化学性质具有有效的抑制作用(IC50:162 nM)。 |
细胞实验 | HeLa cells are maintained in DMEM supplemented with 10% FBS, 2 mM?l-glutamine, 50 U/mL penicillin G, and 50 μg/mL streptomycin. Before use HeLa cells are serum starved for 16 h in DMEM supplemented with 2 mM?l-glutamine, 50 U/mL penicillin G, and 50 μg/mL streptomycin. HeLa cells are then incubated with ERK5-IN-1 at the indicated concentrations for 1 h prior to stimulation with 0.5mol/Lsorbitol for 30 min. Cells are lysed in Triton lysis buffer (50 mM Tris-HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 1 mM sodium pyrophosphate, 0.27mol/Lsucrose, 1 μM microcystin-LR, 1% (v/v) Triton X-100, 0.1% (v/v) 2-mercaptoethanol) and 20 μg of protein loaded per well. Samples are run on 8% polyacrylamide gels using standard methods. Proteins are transferred onto nitrocellulose membranes and specific proteins detected by immunoblotting. |
别名 | XMD17 109, ERK5-IN-1 |
分子量 | 638.8 |
分子式 | C36H46N8O3 |
CAS No. | 1435488-37-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 93 mg/mL (145.6 mM)
Ethanol: 93 mg/mL (145.6 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 1.5654 mL | 7.8272 mL | 15.6544 mL | 39.1359 mL |
5 mM | 0.3131 mL | 1.5654 mL | 3.1309 mL | 7.8272 mL | |
10 mM | 0.1565 mL | 0.7827 mL | 1.5654 mL | 3.9136 mL | |
20 mM | 0.0783 mL | 0.3914 mL | 0.7827 mL | 1.9568 mL | |
50 mM | 0.0313 mL | 0.1565 mL | 0.3131 mL | 0.7827 mL | |
100 mM | 0.0157 mL | 0.0783 mL | 0.1565 mL | 0.3914 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
XMD17-109 1435488-37-1 MAPK ERK Inhibitor inhibit XMD17109 XMD17 109 Extracellular signal regulated kinases ERK5-IN-1 XMD-17-109 inhibitor